



*cancers*



an Open Access Journal by MDPI

## Role of Immunotherapy in Gastroesophageal Cancers: Advances, Challenges and Future Strategies

Guest Editor:

**Dr. Ali Zaidi**

Esophageal and Lung Institute,  
Allegheny Health Network,  
Pittsburgh, PA 15212, USA

Deadline for manuscript  
submissions:

**closed (15 August 2023)**

### Message from the Guest Editor

Dear Colleagues,

In recent years, the use of immunotherapy has led to significant advances in the gastroesophageal cancers treatment landscape with pivotal trials establishing PD-1 blockade as a new standard of care for selected patients, in both respectable and first-line metastatic settings. However, the survival outcomes for the advanced disease are still humbling due to the non-inflamed nature of these tumors, necessitating the development of combinatorial approaches to overcome the resistance to immunotherapy. The aim of our Special Issue is to provide a platform for original research and review articles focused on therapeutic approaches being developed for gastroesophageal cancers to improve the prognosis and survival rates of patients treated with immunotherapies, while addressing the challenges associated with an acquired resistance.

Dr. Ali H. Zaidi

*Guest Editor*



[mdpi.com/si/159879](https://mdpi.com/si/159879)

# Special Issue



# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI